首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1624442

免疫疗法药物市场规模（按治疗领域、最终用户、药物类型、地区、范围和预测）

Immunotherapy Drugs Market Size by Therapy Area, By End-User, By Type of Drugs, By Geographic Scope and Forecast

出版日期: 2024年09月29日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

免疫治疗市场估值，2024 年至 2031 年

免疫治疗药物的需求日益增长，为多种癌症、自体免疫疾病和传染病患者带来了新的希望。与传统疗法不同，免疫疗法利用人体免疫系统来识别和对抗疾病，使其能够针对特定细胞，副作用可能更少。随着全球癌症发病率持续上升，对能够提供持久反应的有效治疗方法的需求正在推动该领域的研究和应用。预计2024年市场规模将超过2,567.8亿美元，2031年将达到约5,687.1亿美元。

检查点抑制剂、CAR-T 细胞疗法和单株抗体等免疫疗法药物在临床试验中已取得巨大成功，进一步促进了它们纳入标准治疗方案和需求。对具有成本效益的免疫疗法药物的需求不断增长，推动市场在 2024 年至 2031 年期间的复合年增长率达到 10.45%。

免疫疗法市场定义/概述

免疫治疗药物是一类旨在增强或改变人体免疫反应以识别和攻击致病细胞的治疗方法。与直接针对疾病的传统治疗方法不同，免疫疗法利用免疫系统瞄准和摧毁异常细胞，通常专注于区分异常细胞和健康细胞的特定标记。这些药物代表了一系列的方法，包括检查点抑制剂、CAR-T 细胞疗法、单株抗体和细胞因子，每种药物都旨在增强免疫反应或降低对疾病细胞的免疫耐受性。免疫疗法在治疗癌症、慢性感染和某些自体免疫疾病方面特别有效，因为它比传统疗法产生更有针对性的反应，副作用也更少。

随着研究不断扩大免疫疗法药物的应用范围，其未来前景十分光明。基因组学和分子生物学的技术进步正在推动下一代免疫疗法的发展，包括基于个体基因特征的个人化治疗。

此外，免疫疗法可望超越原先的癌症治疗，用于治疗自体免疫疾病和传染病。随着我们对免疫途径的理解不断提高，製药业正在大力投资免疫疗法研发，再加上支持性监管政策，可能会扩大免疫疗法的影响和可用性。这些轨迹表明免疫疗法将在未来医学中发挥关键作用，为复杂疾病提供更有针对性和持久的解决方案。

全球癌症发生率的不断上升将如何推动免疫疗法市场？

全球癌症发生率上升是免疫治疗药物市场发展的主要驱动力。根据世界卫生组织估计，2020年癌症死亡人数将达到近1,000万人，预计到2040年新病例数将增加60%，对有效治疗的需求日益增加。根据美国癌症协会报告，免疫疗法药物，尤其是检查点抑制剂，在治疗黑色素瘤等癌症方面已显示出良好的效果，其反应率高达40%，改善了患者的治疗效果。越多的人采用这些疗法来治疗

自体免疫疾病的增加是免疫治疗药物市场的主要动力。根据美国国立卫生研究院统计，美国有超过2,400万人患有自体免疫疾病；而根据美国自体免疫相关疾病协会（AARDA）统计，发生率每年增加19%。由于女性患上这些疾病的可能性是男性的两倍，因此对免疫疗法药物等有效治疗方法的需求迅速增长。这一趋势凸显了对管理和治疗自体免疫疾病的创新疗法的需求，从而推动了市场的成长。

治疗费用的上涨将如何阻碍免疫疗法市场的成长？

治疗费用高是阻碍免疫治疗药物市场成长的主要因素。由于复杂的研究、开发和製造过程，免疫疗法治疗往往费用昂贵，许多患者无法接受治疗，尤其是那些没有足够保险覆盖的患者。这些经济障碍限制了患者接受治疗的机会，儘管免疫疗法有可能用于治疗一系列疾病，但经济问题阻碍了其广泛采用，导致市场占有率有限。

某些患者族群的疗效有限可能会阻碍免疫疗法市场的成长。免疫疗法并不是万能的，有些患者可能会因为遗传、环境和生物因素而反应不佳，限制了其整体影响和采用。治疗结果的这种差异将削弱医疗服务提供者和患者的信心，减缓免疫疗法药物的接受度和广泛使用，最终影响市场成长。

The demand for immunotherapy drugs is rising as these treatments offer new hope for patients with various forms of cancer, autoimmune diseases, and infectious conditions. Unlike traditional therapies, immunotherapy works by harnessing the body's immune system to recognize and fight diseases, making it a powerful alternative that can target specific cells with potentially fewer side effects. As cancer rates continue to climb globally, the need for effective treatments with durable responses has driven research and adoption in this field. The market size surpass USD 256.78 Billion valued in 2024 to reach a valuation of around USD 568.71 Billion by 2031.

Immunotherapy drugs such as checkpoint inhibitors, CAR T-cell therapies, and monoclonal antibodies have shown significant success in clinical trials, further propelling their demand and integration into standard treatment protocols. The rising demand for cost-effective and immunotherapy drugs is enabling the market grow at aCAGR of 10.45% from 2024 to 2031.

Immunotherapy Drugs Market: Definition/ Overview

Immunotherapy drugs are a class of treatments designed to enhance or modify the body's immune response to recognize and attack disease-causing cells. Unlike traditional treatments, which directly target the disease, immunotherapy leverages the immune system to target and destroy abnormal cells, often with a focus on specific markers that distinguish them from healthy cells. These drugs encompass a variety of approaches, including checkpoint inhibitors, CAR T-cell therapies, monoclonal antibodies, and cytokines, each designed to either boost immune responses or reduce immune tolerance to disease cells. Immunotherapy has proven especially effective in treating cancers, chronic infections, and certain autoimmune diseases by creating a more targeted response, with the potential for fewer side effects compared to conventional therapies.

The future scope of immunotherapy drugs is highly promising as research continues to expand its applications across more diseases. Technological advancements in genomics and molecular biology are driving the development of next-generation immunotherapies, including personalized treatments based on an individual's genetic profile.

The use of immunotherapy is also expected to increase in treating autoimmune conditions and infectious diseases, moving beyond its initial focus on oncology. As the understanding of immune pathways grows, the pharmaceutical industry is investing heavily in immunotherapy R&D, which, combined with supportive regulatory policies, is likely to broaden its impact and availability. This trajectory suggests immunotherapy will play a pivotal role in the future of medicine, providing more targeted and durable solutions for complex diseases.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How Will the Rising Cancer Incidence Worldwide Drive the Immunotherapy Drugs Market?

The rising global incidence of cancer is a significant driver for the immunotherapy drugs market. With cancer responsible for nearly 10 million deaths in 2020 and new cases projected to increase by 60% by 2040, according to the WHO, there is a growing demand for effective treatments. Immunotherapy drugs, especially checkpoint inhibitors, have demonstrated promising results with up to 40% response rates in cancers like melanoma, as reported by the American Cancer Society, leading to increased adoption of these therapies to improve patient outcomes.

The growing prevalence of autoimmune diseases is a major driver of the Immunotherapy Drugs Market. According to the NIH, over 24 million people in the United States are affected by autoimmune disorders, and the American Autoimmune Related Diseases Association (AARDA) notes an annual increase of 19% in cases. With women twice as likely to develop these conditions, the demand for effective treatments, such as immunotherapy drugs, is rising rapidly. This trend underscores the need for innovative therapies to manage and treat autoimmune diseases, thus fueling market growth.

How Does the High Cost of Treatment Hamper the Growth of the Immunotherapy Drugs Market?

The high cost of treatment is a significant factor hampering the growth of the Immunotherapy Drugs Market. Immunotherapy treatments are often expensive due to the complex research, development, and production processes involved, making them less accessible to many patients, especially those without adequate insurance coverage. This financial barrier limits patient access to these therapies, restricting market growth as affordability issues deter widespread adoption despite the potential benefits of immunotherapy in treating various diseases.

Limited efficacy in certain patient populations can hamper the growth of the Immunotherapy Drugs Market. Immunotherapy is not universally effective, as some patients may not respond well due to genetic, environmental, or biological factors, which restricts its overall impact and adoption. This variability in treatment outcomes reduces confidence among healthcare providers and patients, slowing down the acceptance and widespread use of immunotherapy drugs and ultimately affecting market growth.

Category-Wise Acumens

Will the Proven Efficacy Propel the Checkpoint Inhibitors Segment for the Immunotherapy Drugs Market?

The checkpoint inhibitors segment is dominating the immunotherapy drugs market. The proven efficacy of checkpoint inhibitors is propelling the checkpoint inhibitors segment in the immunotherapy drugs market. These drugs have shown remarkable success in treating various cancers, especially by enhancing the body's immune response to target and destroy cancer cells more effectively. Their ability to improve survival rates in challenging cases, such as advanced melanoma and lung cancer, has driven strong demand from healthcare providers and patients alike. With ongoing research expanding their use across different cancer types, the efficacy of checkpoint inhibitors continues to strengthen their role in cancer therapy.

The favorable safety profile is propelling the checkpoint inhibitors segment in the Immunotherapy Drugs Market. Checkpoint inhibitors target specific pathways in cancer cells, allowing the immune system to attack cancer more effectively with fewer side effects compared to traditional therapies like chemotherapy. This targeted approach reduces the risk of widespread toxicity, making these drugs safer and better tolerated by patients. As a result, the preference for checkpoint inhibitors is growing, particularly for long-term cancer treatment, driving their demand in the immunotherapy drugs market.

Will the High Prevalence of Diseases Promote the Healthcare Institutions Segment for the Immunotherapy Drugs Market?

The healthcare institutions segment is ruling the immunotherapy drugs market. The high prevalence of diseases, particularly cancer and autoimmune disorders, is promoting the healthcare institutions segment in the immunotherapy drugs market. As the incidence of these diseases rises globally, healthcare institutions are increasingly adopting advanced immunotherapy treatments to improve patient outcomes. Immunotherapy drugs, such as checkpoint inhibitors and monoclonal antibodies, offer promising alternatives to traditional treatments, attracting healthcare providers seeking more effective therapies. The growing demand for innovative treatments within hospitals and clinics is driving the expansion of immunotherapy drug usage in healthcare settings.

Advanced medical infrastructure is promoting the Healthcare Institutions segment in the Immunotherapy Drugs Market. With improved healthcare facilities, technology, and expertise, institutions are better equipped to administer complex immunotherapies, including precision medicine and advanced biologics. The availability of cutting-edge diagnostic tools and treatment protocols enables healthcare providers to deliver these therapies more effectively, improving patient outcomes. As hospitals and clinics enhance their capabilities, the demand for innovative immunotherapy drugs continues to rise, driving growth in this segment.

Country/Region-wise Acumens

Will the Disease Prevalence and Patient Population Accelerate the North American Region for the Immunotherapy Drugs Market?

North America's dominance in the immunotherapy drugs market is driven by several factors. Disease prevalence and a large patient population are accelerating the Immunotherapy Drugs Market in North America. In 2023, the American Cancer Society reported around 1.9 million new cancer diagnoses, with immunotherapy as a primary treatment option, and the National Cancer Institute noted that 40% of U.S. cancer patients are eligible for these therapies. Additionally, autoimmune diseases affect approximately 23.5 million Americans and are rising by 4-7% annually. This high prevalence of cancer and autoimmune conditions creates a substantial demand for immunotherapy treatments, driving market growth in the region.

Advanced healthcare infrastructure is accelerating the Immunotherapy Drugs Market in North America. The region boasts over 1,500 cancer centers offering immunotherapy treatments, and 89% of oncologists now prescribe immunotherapy as a first-line option for eligible patients. Additionally, expanded Medicare coverage for CAR T-cell therapy, now covering 85% of eligible patients, makes these innovative treatments more accessible. This robust infrastructure and supportive coverage landscape enhance patient access and adoption of immunotherapy, driving significant market growth in North America.

Will the Healthcare Infrastructure Improvements Expand the Asia Pacific region for Immunotherapy Drugs Market?

Asia Pacific is rapidly growing in the immunotherapy drugs market. Healthcare infrastructure improvements are driving the Immunotherapy Drugs Market in the Asia Pacific region. China's "Healthy China 2030" initiative emphasizes enhanced cancer care and the development of immunotherapies, while India's National Health Policy 2017 aims for universal health coverage, including access to advanced cancer treatments. Additionally, Japan's substantial investment of JPY 1.1 trillion in healthcare R&D, focusing on innovative oncology therapies, strengthens the region's capacity to support and expand immunotherapy options. These initiatives collectively boost accessibility, research, and adoption of immunotherapies, accelerating market growth in the Asia Pacific.

A supportive regulatory environment is accelerating the Immunotherapy Drugs Market in the Asia Pacific region. In 2023, China's National Medical Products Administration (NMPA) approved 15 new immunotherapy drugs, signaling strong support for these treatments. India's Central Drugs Standard Control Organization (CDSCO) has streamlined approval processes specifically for immune-oncology therapies, while Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has introduced expedited review pathways for breakthrough immunotherapies. These regulatory advancements facilitate faster market entry and access, boosting the availability and adoption of immunotherapy drugs across the Asia Pacific.

Competitive Landscape

The immunotherapy drugs market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the immunotherapy drugs market include:

Roche
Merck & Co.
Bristol-Myers Squibb
Novartis
Pfizer
Amgen
AstraZeneca
Gilead Sciences
Johnson & Johnson
GlaxoSmithKline

Latest Developments

In September 2023, NextCure announced the initiation of a Phase I/II trial (NCT03665285) to evaluate the safety and tolerability of NC318 as a potential treatment for advanced or metastatic solid tumors. The trial includes assessments for conditions such as head and neck squamous cell carcinoma, non-small cell lung cancer, and ovarian cancer.
In January 2022, Immunocore Ltd, a biotechnology company, got FDA clearance for tebentafusp-tebn (Kimmtrak), a bispecific gp100 peptide-HLA-directed CD3 T cell engager, for adult patients with unresectable or metastatic uveal melanoma and HL:01.

1 INTRODUCTION OF GLOBAL IMMUNOTHERAPY DRUGS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL IMMUNOTHERAPY DRUGS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA

5.1 Overview
5.2 Cancer
5.3 Autoimmune and Inflammatory Diseases
5.4 Infectious Diseases
5.5 Other Therapy Areas

6 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END-USER

6.1 Overview
6.2 Hospitals
6.3 Clinics
6.4 Others

7 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE OF DRUG

7.1 Overview
7.2 Monoclonal Antibodies
7.3 Adult Vaccines
- 7.3.1 Preventive Vaccines
- 7.3.2 Therapeutic Vaccines
7.4 Checkpoint Inhibitors
7.5 Interferons Alpha & Beta
7.6 Interleukins
7.7 Other Drugs

8 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL IMMUNOTHERAPY DRUGS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Share
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 F. Hoffmann-La Roche Ltd. (UK)
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Merck & Co (US)
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Novartis International AG (UK)
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Johnson & Johnson (US)
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Sanofi (France)
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 GlaxoSmithKline Plc (UK)
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Amgen Inc. (US)
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 AbbVie Inc. (US)
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Boehringer Ingelheim (Germany)
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 AstraZeneca (UK)
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments